ZFP36L1 and ZFP36L2 are RNA-binding proteins (RBPs) that interact with AU-rich elements in the 3′ untranslated region of mRNA, which leads to mRNA degradation and translational repression. Here we show that mice that lacked ZFP36L1 and ZFP36L2 during thymopoiesis developed a T cell acute lymphoblastic leukemia (T-ALL) dependent on the oncogenic transcription factor Notch1. Before the onset of T-ALL, thymic development was perturbed, with accumulation of cells that had passed through the -selection checkpoint without first expressing the T cell antigen receptor -chain (TCR). Notch1 expression was higher in untransformed thymocytes in the absence of ZFP36L1 and ZFP36L2. Both RBPs interacted with evolutionarily conserved AU-rich elements in the 3′ untranslated region of Notch1 and suppressed its expression. Our data establish a role for ZFP36L1 and ZFP36L2 during thymocyte development and in the prevention of malignant transformation.
The development of T cells in the thymus proceeds through a series of developmental stages characterized by progressive rearrangement of the T cell antigen receptor (TCR) genes and regulated by a series of developmental checkpoints. This ordered process is orchestrated by transcription factor networks that integrate environmental cues to initiate gene-expression programs appropriate to the developmental stage of the thymocyte [1] [2] [3] . However, there is increasing recognition that gene expression during lymphocyte development is also subject to regulation by post-transcriptional mechanisms. These affect the half-life of mRNA though the promotion or inhibition of mRNA decay. Additional control at the point of mRNA translation also regulates the magnitude of gene expression. These points are exemplified by awareness of the regulation of gene expression by microRNAs that act principally through the control of mRNA decay and translation. Post-transcriptional control of gene expression is also mediated by RNA-binding proteins (RBPs), of which over 150 have been found to be expressed in thymus 4 . However, knowledge of how posttranscriptional regulation mediated by RBPs affects thymic development is extremely limited.
ZFP36L1 and ZFP36L2 (also known as TIS11b and TIS11d) belong to a family of CCCH zinc finger-containing RBPs that includes ZFP36 (tristetraprolin). These regulate gene expression by promoting mRNA decay and might additionally affect translation. Mice with germline deletion of Zfp36 develop a severe inflammatory phenotype attributable to overexpression of tumor necrosis factor 5, 6 , whereas germline deletion of Zfp36l1 is lethal at embryonic day 10.5 because of a failure of chorioallantoic fusion 7, 8 . Mice with germline deletion of Zfp36l2 die shortly after birth, possibly as a consequence of hematopoietic stem cell failure 9 . The tandem zinc fingers are highly conserved among ZFP36 family members and bind to AU-rich elements in the 3′ untranslated region (3′ UTR) of mRNA, which promotes deadenylation and decay. The optimum binding sequence for all family members is UUAUUUAU 10, 11 . However, sequences as short as UAUUU may be sufficient for binding, and genome-wide screens to identify targets have been enriched with transcripts that do not have the optimal AUrich binding site 12 . Thus, the criteria for target recognition and whether this differs among the family members remain incompletely defined.
There is mounting evidence that escape from post-transcriptional regulation of gene expression is important in the pathogenesis of malignancy. Deletion of the cluster of microRNAs miR15a and miR16-1 in mice leads to the development of a disease similar to human chronic lymphocytic leukemia 13 . Aberrant use of polyadenylation sites, which leads to a truncated 3′ UTR, has been detected in many human malignancies and might allow malignant cells to escape regulation by both microRNA and RBPs 14, 15 . As a physiological mechanism, proliferating T cells preferentially use truncated 7 1 8 VOLUME 11 NUMBER 8 AUGUST 2010 nature immunology A r t i c l e s 3′ UTRs 16 . This is consistent with the provision of a net proliferative advantage by a global decrease in post-transcriptional regulation. Circumstantial evidence has linked ZFP36 family members to malignancy. Expression of ZFP36 is suppressed in a variety of human malignancies 17 . ZFP36L2 has been suggested to act downstream of the tumor suppressor p53 in the induction of apoptosis, and ZFP36L1 has been linked to the apoptotic response to rituximab (antibody to CD20 (anti-CD20)) in chronic lymphocytic leukemia 18, 19 . Many oncogenes, including FOS, MYC, BCL2 and PTGS2, contain AU-rich elements in their 3′ UTRs and have been proposed as potential targets 20 . However, no evidence so far has proven an in vivo physiological tumor-suppressor role for ZFP36 family members or indeed any RBP.
To investigate the function of ZFP36L1 and ZFP36L2 in thymic development, we generated mice with conditional deletion of the genes encoding both proteins. In anticipation of redundancy between these two closely related family members, we intercrossed mice with single deletion to create mice with conditional deletion of Zfp36l1 and Zfp36l2 in lymphocytes (double-knockout ('dKO') mice). Thymic development was normal in mice with single deletion of Zfp36l1 or Zfp36l2; however, the dKO mice developed T cell acute lymphoblastic leukemia (T-ALL). Before the leukemia developed, the normally ordered process of thymic development was perturbed, with aberrant passage of thymocytes through the β-selection checkpoint. Furthermore, we identified the oncogenic transcription factor Notch1 as a target of ZFP36L1 and ZFP36L2. The finding that a transcription factor is itself a target for post-transcriptional regulation demonstrates how RBPs integrate gene expression at the transcriptional and post-transcriptional level. Our findings identify a critical role for ZFP36 family members during lymphocyte development and provide strong evidence for their function as tumor suppressors.
RESULTS
T-ALL development in dKO mice ZFP36L1 and ZFP36L2 were expressed throughout thymic development, especially during the early CD4 − CD8 − double-negative (DN) stages (Supplementary Fig. 1 ). To examine their function, we generated mice with conditional deletion by standard genetargeting techniques (Supplementary Fig. 2 ). We intercrossed mice and bred them to homozygosity for loxP-flanked alleles of both Zfp36l1 (Zfp36l1 fl/fl ) and Zfp36l2 (Zfp36l2 fl/fl ). We used transgenic expression of Cre recombinase under the control of the human CD2 locus-control region to effect deletion before the DN1 stage of thymic development 21, 22 . Unless stated otherwise, control mice were Zfp36l1 fl/fl Zfp36l2 fl/fl . We confirmed that expression of the CD2-Cre transgene alone caused no associated defect in thymic development (data not shown). Zfp36l1 fl/fl Zfp36l2 fl/fl CD2-Cre (dKO) mice were born at expected Mendelian ratios and seemed healthy in early life. However, by 6 months of age, 90% of the dKO mice died or were humanely killed because of their ill health (Fig. 1a) . All of these mice had developed thymic tumors and many also showed splenomegaly and lymphadenopathy (Supplementary Fig. 3 ). We never observed tumor development in Zfp36l1 fl/fl CD2-Cre or Zfp36l2 fl/fl CD2-Cre (Fig. 1b) . Tumor cells had high expression of heat-stable antigen (CD24) but did not have surface expression of the TCR β-chain (TCRβ). Most but not all tumors had intracellular expression of TCRβ (icTCRβ). We found circulating lymphoblasts when we examined the peripheral blood (Fig. 1c,d ). Flow cytometry of spleen, lymph node and bone marrow frequently demonstrated involvement by tumor cells of a phenotype identical to that of the associated thymic tumor (Fig. 1e) . Clonality testing by PCR across the TCRβ2 region suggested that thymic tumors were predominantly oligoclonal (Fig. 1f) .
Together these findings suggest that deletion of Zfp36l1 and Zfp36l2 together leads to the development of T-ALL corresponding to the CD8 + immature single-positive (CD8iSP) and double-positive (DP) stages of thymic development.
Perturbed thymopoiesis before tumor development
In dKO mice, tumor development was preceded by thymic atrophy. At 3 and 8 weeks of age, total thymic cellularity in dKO mice was approximately 50% that of control mice (Fig. 2a,b ). This atrophic stage was associated with the gradual expansion of the CD8iSP population (CD8 + CD4 − CD24 hi , membrane TCRβ negative). By 13 weeks this population was considerably expanded in both proportion and absolute number (Fig. 2c,d ). We also observed abnormal development at the CD4 − CD8 − (DN) stages (Fig. 2e) . The expression of CD44 and CD25 is used to describe four stages of DN development and seemed to show less progression from DN2 (CD44 + CD25 + ) to DN3 (CD44 − CD25 + ; Fig. 2e) . However, the utility of this staining strategy for describing functional progression in the face of perturbed thymic development is limited. Therefore, we examined icTCRβ expression, which normally begins during the DN3 stage after successful TCRβ rearrangement. In dKO mice, the proportion of DN thymocytes with icTCRβ expression was much lower ( Fig. 2e and Supplementary Fig. 4 ).
In wild-type mice, icTCRβ expression is a prerequisite for passage of cells through the β-selection checkpoint. However, in dKO mice, these icTCRβ − cells showed features of metabolic activation normally only seen after β-selection. Expression of the amino acid transporter CD98 and the transferrin receptor CD71 is normally low before β-selection but increases in a Notch1-dependent manner after β-selection as cellular metabolism increases 23 . However, expression of CD98 and CD71 was high in all DN thymocytes from dKO mice (Fig. 2e) , which suggested metabolic activation even in icTCRβ − thymocytes. Consistent with that finding, icTCRβ − dKO cells showed more forward scatter, typical of 'blasting' cells (data not shown). Furthermore, cellular proliferation was greater, as judged by more uptake of 5-ethynyl-2′-deoxyuridine after pulse administration of this thymidine analog (Supplementary Fig. 5 ). Thus, it seemed that dKO thymocytes were able to transit the β-selection checkpoint with the associated metabolic activation and proliferation but without expression of TCRβ. This aberrant passage through β-selection was associated with differentiation of icTCRβ − thymocytes to the CD8iSP and DP developmental stages, which lie downstream of β-selection. As expected, in control mice, all thymocytes from the CD8iSP and DP stages had icTCRβ expression. However, in dKO thymocytes, only 30% of CD8iSP cells had icTCRβ expression ( Fig. 2e and Supplementary Fig. 4 ). This increased to 90% of DP cells and 100% at the CD4 + and CD8 + mature SP stages ( Supplementary Fig. 4 ). Thus, although dKO icTCRβ − cells were able to pass β-selection, they were unable to progress beyond the DP stage. Despite the accumulation of TCRβ − CD8iSP cells, most thymic tumors corresponded to TCRβ + CD8iSP thymocytes, which suggests the importance of pre-TCR signals during the development of leukemia. 
A r t i c l e s Higher Notch1 expression in dKO thymocytes
We hypothesized that the thymic phenotype observed in dKO mice might result from the overexpression of one or more genes normally suppressed by ZFP36L1 or ZFP36L2. We did microarray analysis of whole thymus from control and dKO mice at 5 weeks and 9 weeks of age, as this was before the development of tumor; at 5 weeks of age, the relative thymic proportions were normal, as judged by staining for CD4 and CD8 (Fig. 1a) . At 9 weeks of age, more than 500 genes with a significant change (P < 0.05) had expression that was more than 1.5-fold higher. Fewer had higher expression at 5 weeks. When we filtered the list to include only genes with higher expression in both the 5-week and 9-week arrays, we identified 17 named genes (Fig. 3a) . Of those 17 upregulated genes, we chose to investigate further the expression of Notch1, as this gene is critical for thymic development and in the pathogenesis of T-ALL 24 . We confirmed by real-time PCR higher expression of mRNA for Notch1 and its target genes Hes1, Myc and Dtx1 (Fig. 3b) . We also found high expression of Notch1 protein in thymic tumors by both immunoblot analysis and flow cytometry (Fig. 3c,d ). Notch1 expression, as assessed by flow cytometry, was between 5-fold and 50-fold higher in thymic tumors than in control thymus (Fig. 3d) . Notch1 staining was greater in thymic tumors than any individual subpopulation of control thymus (Fig. 3e) , which suggested that the higher expression in tumors did not merely reflect an expansion of immature populations. We also examined Notch1 expression in individual thymic subsets in mice before tumor development. In mice 3 weeks of age, Notch1 expression was higher at the DN stages. We found higher Notch1 expression in both CD25 + icTCRβ − and CD25 + icTCRβ + DN thymocytes (Fig. 3f) . We also found higher Notch1 expression at the CD8iSP stage. In dKO mice, both icTCRβ + and icTCRβ − CD8iSP populations had high expression of Notch1 (Fig. 3g) . Thus, Notch1 expression was abnormally higher in both DN and CD8iSP thymocytes from dKO mice before the onset of T-ALL. This high expression of Notch1 was even greater in dKO tumor cells.
Notch1 is a target of ZFP36L1 and ZFP36L2 The 1.6-kilobase 3′ UTR of Notch1 contained a region of particularly high interspecies conservation in the 300 base pairs after the translationtermination codon (Fig. 4a) . In this highly conserved region (HCR), the greatest interspecies conservation was clustered into three short regions. Notably, each of these contained a predicted ZFP36L1-and ZFP36L2-binding site (Fig. 4b) . These binding sites were not present elsewhere in the Notch1 3′ UTR. When we examined the 3′ UTRs of all 17 genes upregulated in the microarray, Notch1 was the only gene that contained the nonameric AU-rich element considered to be the optimum binding site for ZFP36L1 and ZFP36L2. To determine whether the Notch1 3′ UTR could mediate suppression by ZFP36L1 or ZFP36L2, we introduced the complete Notch1 3′ UTR downstream of the luciferase-coding region in the vector backbone pSI-Check2. When we transfected this reporter into HEK293T human embryonic kidney cells (which do not constitutively express ZFP36L1 or ZFP36L2), cotransfection of vector for either ZFP36L1 or ZFP36L2 suppressed luciferase activity in a dose-dependent manner (Fig. 4c,d ). This effect required functional RNA-binding zinc fingers of ZFP36L1, as a mutant version of ZFP36L1, in which both fingers were altered and could no longer bind RNA (the tandem zinc-finger mutant (TZFM)) failed to suppress the Notch1 UTR reporter (Fig. 4c) . Furthermore, a reporter containing only the HCR was suppressed by ZFP36L1 and ZFP36L2, but these had no effect on a reporter containing the remainder of the UTR lacking the HCR. In all of these assays, we confirmed by immunoblot analysis expression of ZFP36L1, ZFP36L2 and TZFM (data not shown). To demonstrate direct physical interaction between ZFP36L1 or ZFP36L2 and the Notch1 3′ UTR, we used a radiolabeled probe (corresponding to 61 nucleotides of the Notch1 3′ UTR containing the nonameric binding site) in an electrophoretic mobility-shift assay (EMSA). Lysates from HEK293T cells transfected with empty vector or with the TZFM expression vector failed to retard migration of the probe. In contrast, lysates of cells transfected with vector for ZFP36L1 or ZFP36L2 yielded a probe complex with retarded mobility indicative of a direct interaction (Fig. 4e) . The sizes of these complexes correlated with the molecular masses of ZFP36L1 (36 kilodaltons) and ZFP36L2 (50 kilodaltons). Together these results indicate a direct interaction between ZFP36L1 or ZFP36L2 and the HCR of the Notch1 3′ UTR and that this interaction mediates a suppressive effect on gene expression.
Infrequent Notch1 mutation in dKO tumors
Mutation of the proline-glutamic acid-serine-threonine (PEST) domain sequence of the gene encoding Notch1 is frequently found A r t i c l e s in human and mouse models of T-ALL and renders Notch1 protein resistant to degradation. Mutation of the heterodimerization domain is also observed and leads to spontaneous cleavage of Notch1, which leads to ligand-independent signaling activity 25 . We consider it likely that the absence of ZFP36L1 and ZFP36L2 explained the higher Notch1 expression observed in thymocytes before the development of leukemia. However, the oligoclonal nature of the tumors suggests a second hit, possibly leading to activation of an already overexpressed Notch1 receptor. To examine this possibility, we sequenced the PEST and heterodimerization domains of Notch1 in thymic tumors from 12 dKO mice. We detected one mutation of the PEST domain (which resulted in the insertion of a cytidine residue in the position encoding amino acid 2421 of the protein, leading to frame shift and a premature stop). We found three heterodimerization mutations (all T-to-C point mutations), reported before in both human and mouse T-ALL, that lead to a leucine-to-proline switch at amino acid residue 1668 (ref. 25) . Thus, Notch1 mutation was present in a minority of tumors and affected mainly the heterodimerization domain (25%) rather than the PEST domain (8%).
Tumors are Notch1 dependent and killed by ZFP36L1 re-expression To establish if tumors were Notch1 dependent, we cultured primary tumor cells from dKO mice on OP9 mouse bone marrow stromal cells expressing the Notch ligand DL1 (OP9-DL1 cells) in the presence of increasing concentrations of the γ-secretase inhibitor compound E, which inhibits Notch signaling. After 72 h, we counted cells and analyzed them by flow cytometry (Fig. 5a) . Tumor growth was sensitive to compound E, which was effective at concentrations as low as 0.1 μM. To establish if tumor development was Notch1 dependent in vivo, we treated 12-week-old mice with a Notch1-blocking antibody or saline (control). This antibody is directed against the extracellular negative-regulatory region of Notch1 and stabilizes its inactive state 26 .
In control mice that received the Notch1-blocking antibody, thymic cellularity was diminished to <1% of normal cellularity, and this consisted predominantly of mature CD4 + or CD8 + SP cells (Fig. 5b,c) . This demonstrated the ability of the antibody to block Notch1 signaling. Of the dKO mice that received saline injections, thymic tumors were present in two (20%), and all showed grossly abnormal thymic populations by flow cytometry (Fig. 5c) . We found no tumors in dKO mice that received the Notch1-blocking antibody, and most had thymic cellularity <1% of normal cellularity. Two mice in this cohort had an apparently enlarged thymus that consisted of predominantly necrotic cells. We consider it likely that these represented pre-existing thymic tumors that were killed by Notch1 blockade. Treatment with antiNotch1 also led to the disappearance of CD8 + CD4 − CD24 hi icTCRβ − and CD8 + CD4 − CD24 hi icTCRβ + populations in the dKO mice (Fig. 5c) , which indicated that the population expansion or maintenance of these cells in vivo was Notch1 dependent.
To establish the effect of re-expression of ZFP36L1 on tumors cultured in vitro, we cultured primary tumor cells on OP9-DL1 cells and then infected them with equivalent titers of retrovirus expressing green fluorescent protein and either ZFP36L1 or TZFM. Notably, cultures were almost completely depleted of ZFP36L1-expressing cells (Fig. 5d) , which confirmed that expression of ZFP36L1 is toxic to primary tumor cells. Together these results suggest that the growth and survival of dKO tumor cells remained dependent on active Notch1 signaling and on the absence of ZFP36L1.
DISCUSSION
At present, models of thymocyte development have focused predominantly on regulation of gene expression at the level of the transcription factor. A role for post-transcriptional regulation of gene expression has been proposed in the context of microRNA 27 . However, post-transcriptional regulation is also mediated by RBPs. So far, the predominant understanding of the role of RBPs in the immune system has been about their ability to regulate the stability of mRNA for short-lived cytokines involved in the inflammatory response. Knowledge of their role during thymopoiesis is limited to a single report describing defective egress of mature thymocytes from the thymus of mice with deletion of the RBP Elavl1 (ref. 28) . Therefore, the data presented here have established a previously unknown requirement for ZFP36L1 and ZFP36L2 during normal thymic development. Furthermore, they have provided evidence of a critical role for ZFP36L1 and ZFP36L2 in the prevention of lymphoid malignancy.
Close to 100% of dKO mice developed T-ALL beginning at the age of 3 months. We found this phenotype only in dKO mice and never in mice of any intermediate combination of genotypes, which suggested a large degree of redundancy between these two highly homologous proteins. The evolutionary need for such redundancy is consistent with the critical role demonstrated here in the prevention of malignancy. The absence of leukemia in mice of any genotype other than the dKO mice is evidence that challenges the idea that the phenotype was due to an artifact of gene targeting. The toxicity of ZFP36L1 when re-expressed in tumor cells is further evidence that the leukemic phenotype did indeed result from the loss of ZFP36L1 and ZFP36L2. The involvement of ZFP36 family members in malignancy has been suggested before 20 . Expression of ZFP36 family members is suppressed in a range of human cancers, and a tumor-suppressor role has been proposed to act through regulation of proliferative and antiapoptotic factors 17, 20 . However, this is the first example to our knowledge in which intentional deletion of an RBP led to the development of malignancy. Before the development of T-ALL, thymic development is perturbed. In particular, thymocytes seem able to bypass β-selection in the absence of a functional TCRβ chain. In mice doubly deficient in recombination-activating genes 1 and 2 or mice deficient in TCRβ, DP differentiation can be partially restored by deletion of genes encoding the transcription factors Ikzf1 or TCF3 or the tumor suppressor Trp53 or by transgenic overexpression of genes encoding the GTPase Ras, the mitogen-activated protein kinase MAP2K1 or Notch1 (refs. 29-32) . However, dKO thymocytes were able to recombine the TCRβ chain yet seemed unable to suppress the developmental progression of TCRβ − thymocytes. Overexpression of Notch1 in dKO mice might contribute to this aspect of the phenotype. The higher metabolic activity of DN thymocytes is also consistent with higher expression of Notch1, which is known to promote cellular metabolism in cells at the stage of β-selection 33 . Notably, expression of CD98 and CD71 in normal thymocytes is promoted in a Notch1-dependent manner 23 . This proves further evidence that in the absence of both ZFP36L1 and ZFP36L2, Notch1 activity is abnormally greater in DN thymocytes.
The overexpression of Notch1 observed before and after the development of leukemia is also notable, as both chimeric mice reconstituted with bone marrow transduced with retrovirus expressing the Notch1 intracellular domain and other mouse models that overexpress Notch1 invariably develop T-ALL 24, [34] [35] [36] . The observed phenotype of Notch1-driven T-ALL typically corresponds to the CD8iSP and DP stages of thymocyte development and closely resembles the T-ALL seen in the dKO mice. The population expansion of CD8iSP cells was Notch1 dependent in the dKO mice before the onset of T-ALL. The results of luciferase and EMSA experiments suggested that the higher Notch1 expression probably resulted from alleviation of ZFP36L1-and ZFP36L2-mediated suppression. Regulation of Notch1 at the post-transcriptional level has been proposed before in the context of leech development 37 but has not been proposed in the context of thymic development. The degree of increase in Notch1 in dKO mice before onset of leukemia was modestabout twofold. However, we consider this important because Notch1 is normally regulated extremely tightly at the level of both transcription and protein stability. The Notch signaling pathway contains no amplification stage; therefore, one ligand-receptor engagement leads to one molecule of Notch intracellular domain in complex with a single promoter and activation of transcription from a single target allele. Notch1 is also unusual in that a thymic phenotype has been described in the context of haploinsufficiency 38 . These factors suggest that the Notch1 signaling pathway has evolved to regulate its expression within very tight limits.
Notably, overexpression of Notch1 is able to contribute to both the leukemic phenotype and the aberrant β-selection 24, 31 . This contribution of Notch1 to the leukemic phenotype was demonstrated by the Notch1 dependency of tumor cells both in vivo and in vitro. However, it is unclear whether the degree of higher expression was by itself sufficient to initiate leukemia formation. The oligoclonal nature of the tumors suggests a second hit. This might be mutation of Notch1 itself that leads to the cooperative activation of the Notch1 receptor that is already overexpressed in dKO thymocytes. It is also likely that additional unidentified ZFP36L1 and ZFP36L2 targets exist that contribute to the leukemic phenotype. We chose to pursue Notch1 because of its established role in thymic development and the presence of predicted ZFP36L1-and ZFP36L2-binding sites in the Notch1 3′ UTR. However, ZFP36 family members are promiscuous in their binding requirements and targets might exist that do not contain the classic AUrich nonamer 12 . Furthermore, our microarray experiment would not have detected target genes regulated purely at the level of translation. It is recognized that both microRNA and RBPs frequently regulate multiple target mRNAs that encode genes with similar functions-the so-called 'RNA regulons' 39 . Therefore, Notch1 might represent one component of a coordinated program of gene expression (normally suppressed by ZFP36L1 and ZFP36L2) that regulates the 'activation status' of developing thymocytes and, in the absence of ZFP36L1 and ZFP36L2, acts together to promote the leukemic phenotype.
Although we have shown here that ZFP36L1 and ZFP36L2 were able to regulate expression of Notch1, it is notable that Zfp36l2 has been identified before as a gene positively regulated by Notch1, which suggests that Notch1 induces the expression of its own negative regulator 40 . This is consistent with the mRNA expression pattern of ZFP36L1 and ZFP36L2; this expression is high during the early DN stages but decreases at the DN4 stage concurrent with a decrease in Notch1. ZFP36L1 and ZFP36L2 are also regulated post-translationally, and their activity is suppressed by phosphorylation by protein kinase B and by the mitogen-activated protein kinase MAPKAP2 (refs. [41] [42] [43] . There is considerable evidence of interaction between the phosphatidylinositol-3-OH kinase (PI(3)K) and Notch signaling pathways, and phosphorylation of ZFP36L1 and ZFP36L2 might provide a further mechanism by which PI(3)K activity is able to increase Notch1 expression 44, 45 . Both the PI(3)K and mitogen-activated protein kinase signaling pathways have a crucial role during thymocyte development; in addition to their established roles, this could also reflect their ability to regulate gene expression at the post-transcriptional level by controlling the activity of RBPs such as ZFP36L1 and ZFP36L2. The instantaneous and reversible manner in which ZFP36L1 and ZFP36L2 activity can be regulated by phosphorylation is well suited to the changes in gene expression required during thymocyte development. This would provide a mechanism whereby PI(3)K or mitogen-activated protein kinase activity could effect rapid changes in expression of transcription factors such as Notch1, thereby integrating extracellular cues with both post-transcriptional and transcriptional control of gene expression.
Our finding that Notch1 can be regulated at the RNA level is of potentially great importance to human disease. NOTCH1 is mutated in >50% of human T-ALL, and cooperating mutations affecting both the heterodimerization domain and PEST domain are frequent 46 . Truncation of the 3′ UTR as a result of alternative use of the polyadenylation site is commonly seen in malignancy, and it is plausible that mutation or truncation of the NOTCH1 3′ UTR might act together with mutations in coding sequences to further increase Notch1 activity. Preliminary experiments involving analysis of microarray-based comparative genomic hybridization data from 69 human T-ALL samples have identified recurrent deletions in chromosome 14q24, including the ZFP36L1 locus in three cases. This finding is notable but of uncertain importance, as these were nonfocal, heterozygous deletions encompassing several other genes in addition to ZFP36L1. No genetic alterations involving ZFP36L2 in chromosome 2 were present in this series. However, many alternative mechanisms might lead to suppression of ZFP36L1 and ZFP36L2 activity, including epigenetic or post-translational modification by altered kinase or phosphatase activity in leukemic cells. Similarly, defects downstream of ZFP36L1 or ZFP36L2 in the RNA-regulation pathway might contribute to the pathogenesis of human malignancy.
In summary, our data have shown a critical role for the RBPs ZFP36L1 and ZFP36L2 during thymocyte development. They highlight the substantial effect of post-transcriptional regulation of gene expression during thymic development. Furthermore, they also demonstrate a critical role for these proteins as tumor suppressors in the prevention of malignant transformation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. Accession code. ArrayExpress: microarray data, E-MEXP-2737.
Note: Supplementary information is available on the Nature Immunology website.
